The Trip Report
#6: Dr. Jeeshan Chowdhury – A Contrarian Approach to Psychedelic Drug Development
Episode guests
Podcast summary created with Snipd AI
Quick takeaways
- Journey Colab is developing a synthetic form of mescaline, embracing longer trips lasting 12 to 14 hours, challenging the trend of engineered shorter trips or non-hallucinogenic compounds.
- Journey Colab aims to integrate psychological and community support into clinical trials by partnering with rehab centers, emphasizing the importance of safe and high-quality psychedelic care while collaborating with established systems.
Deep dives
Psychedelics and the Square Peg Round Hole Problem
The podcast episode discusses the challenge of integrating psychedelics into existing infrastructure in psychiatry and mental health. The speaker emphasizes that psychedelics are not just pills, but complex substances that require additional components for effective treatment. The issue arises when trying to fit these complex substances into the existing round holes of traditional psychiatric treatments. The speaker mentions that some people have been cutting corners and trying to find ways to make psychedelics less psychoactive or shorter-lasting, but research suggests that these approaches may not be effective. The speaker expresses a preference for high-quality care that incorporates intensive psychotherapy, and highlights the opportunity to integrate psychedelics into existing rehab centers that already offer evidence-based care. The speaker acknowledges the challenges and stigma surrounding medication-assisted treatments in rehab settings, but believes that a new model integrating psychedelics into rehab can provide safe and effective care at scale.
Remember Everything You Learn from Podcasts
